The BNIP3L Knockout HT29 Polyclonal Cells are a polyclonal population of HT29 colorectal adenocarcinoma cells engineered by CRISPR/Cas9-mediated gene disruption to ablate functional BNIP3L protein expression. This knockout product format provides a heterogeneous pool of BNIP3L-null cells, avoiding clonal artifacts while enabling robust investigation of BNIP3L-dependent phenotypes in a well-characterized epithelial cancer model.
The HT29 cell line is a human colorectal adenocarcinoma line isolated from a 44-year-old Caucasian female with primary colon carcinoma. These cells exhibit epithelial morphology and harbor key oncogenic mutations, including TP53 R273H and BRAF V600E, making them a widely used model for colorectal cancer biology. HT29 cells can undergo enterocytic differentiation under appropriate conditions, adding versatility for studying differentiation-related processes and the role of BNIP3L in cell death regulation.
BNIP3L is a pro-apoptotic BH3-only protein and selective mitophagy receptor that binds Atg8-family proteins (LC3/GABARAP) via its LIR motif, targeting damaged mitochondria for autophagic degradation. It also promotes intrinsic apoptosis by neutralizing anti-apoptotic Bcl-2 members such as BCL2L1 and MCL1, facilitating BAX/BAK-dependent mitochondrial outer membrane permeabilization, cytochrome c release, and activation of caspase-9 and caspase-3. Upstream regulators including HIF1A, E2F1, and FOXO3 transcriptionally control BNIP3L expression, linking it to hypoxia and cell cycle pathways. BNIP3L interacts with mitophagy effectors MAP1LC3B, GABARAPL1, and BECN1, and its pathway integrates ULK1, ATG5, ATG7, and PIK3C3 to coordinate autophagic flux with apoptosis.
In HT29 colon carcinoma cells, BNIP3L knockout provides a system to dissect autophagy-apoptosis interplay in colorectal cancer progression. The TP53 R273H and BRAF V600E mutations alter stress responses; BNIP3L ablation allows investigation of how mitophagy deficiency impacts adaptation to hypoxia, metabolic stress, and chemotherapeutics like 5-fluorouracil. This model is relevant for studying resistance mechanisms, as BNIP3L-mediated mitophagy can either suppress tumorigenesis through mitochondrial quality control or promote survival under treatment.
Researchers can employ these polyclonal knockout cells in immunoblotting for LC3-II and BNIP3L, flow cytometry with MitoTracker, and Annexin V/PI apoptosis assays. Co-immunoprecipitation can probe BNIP3L interactions with LC3/GABARAP members, and hypoxia chamber mitophagy flux analysis can reveal functional outcomes. The cells are suitable for xenograft tumor growth studies in immunodeficient mice to assess BNIP3L impact on tumorigenicity and drug response in vivo. Further information is available from Ascent Research.
